CELC
Celcuity Inc.
NASDAQ · Healthcare · Biotechnology · US
$68.72
−1.44%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$70.93
From 52W high−52.60%
Volume326284.00
Market cap$3.36B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$70.93
From 52W high
−52.60%
Volume
326284.00
Market cap
$3.36B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−18.2x
P/E (TTM)
—
RSI (14)
49.8
MomentumView details →
1D Return
−1.44%
YTD Return
−30.59%
SummaryUpdated Jun 1, 2026
Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company founded in 2011 and headquartered in Minneapolis, Minnesota. The company went public in September 2017 and focuses on developing molecularly targeted cancer therapies. Celcuity operates through two main platforms: its lead drug candidate <b>gedatolisib</b>, which targets multiple cancer pathways simultaneously, and its proprietary <b>CELsignia diagnostic platform</b> that uses living tumor cells to identify specific cellular processes driving individual patients' cancers. The company is currently in late-stage clinical trials with potential regulatory approval on the horizon for 2025-2026.
Similar companies
Latest newsMore news →
Celcuity announced that it will release its third-quarter 2026 financial results after the market closes on November 5, 2026, and hold a webcast and conference call that day at 4:30 p.m. Eastern Standard Time.6d agoCelcuity Inc. presented updated Phase 3 VIKTORIA-1 results for patients with HR+/HER2- advanced breast cancer and no liver metastases, reporting median progression-free survival of 21.5 months with the gedatolisib triplet, 11.5 months with the gedatolisib doublet, and 9.1 months with alpelisib plus fulvestrant.11d agoCelcuity Inc. announced that a late-breaking rapid oral presentation and three poster presentations on its gedatolisib clinical trial data will be featured at the ESMO Congress 2026, to be held October 23-27, 2026, in Madrid, Spain.30d ago